Skip to main content

Advertisement

SpringerLink
Log in

Outcome measures in psoriatic arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Psoriatic arthritis (PsA) is an important condition that significantly impacts affected patients. The introduction of novel therapeutic agents for PsA has generated great interest in clinical trials as well as in clinical care. Therefore, there is a great need for standardized outcome measures that can accurately assess the activity of disease and response to therapy. Because it is a heterogeneous and multifaceted condition, defining outcome measures has been a challenge. To date, such measures have largely been adapted from other similar diseases. With further research, the most appropriate outcome measures specific for PsA will be delineated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gladman D, Espinoza L: International symposium on psoriatic arthritis. J Rheumatol 1992, 19:290–291.

    PubMed  CAS  Google Scholar 

  2. McHugh N, Balachrishnan C, Jones S: Progression of peripheral joint disease in PsA; a 5 year prospective study. Rheumatology 2003, 42:778–783. A carefully performed study that provides key information on prognostic factors for patients with PsA.

    Article  PubMed  CAS  Google Scholar 

  3. Gladman D, Farewell V, Wong K, et al.: Mortality studies in psoriatic arthritis; results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998, 41:1103–1110. A comprehensive analysis of a large clinic population of PsA.

    Article  PubMed  CAS  Google Scholar 

  4. Mease P: Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Annals Rheum Dis 2002, 61:298–304.

    Article  CAS  Google Scholar 

  5. Gottlieb A, Antoni C: Treating psoriatic arthritis: how effective are TNF antagonists. Arthritis Res Ther 2004, 6(Suppl 2):S31-S35.

    Article  PubMed  CAS  Google Scholar 

  6. Vaz A, Barton J, Ritchlin C: Psoriatic arthritis: an update for clinicians. Int J Adv Rheumatol 2004, 2:126–134. A recent review on psoriatic arthritis, with updates on important recent information, in particular as it relates to bone damage and its mechanisms.

    Google Scholar 

  7. Gladman D, Farewell V, Buskila D, et al.: Reliability of measurements of active and damaged joints in psoriatic arthritis. J Rheumatol 1990, 17:62–64.

    PubMed  CAS  Google Scholar 

  8. Taylor WJ: Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol 2004, 16:350–356. An excellent consideration of outcome measurements in PsA, with a focus on methods and validation.

    Article  PubMed  Google Scholar 

  9. Gladman D, Helliwell P, Mease P, et al.: Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24–35. An excellent, thorough assessment of many varied outcome measurements in PsA, along with relevant historic considerations.

    Article  PubMed  Google Scholar 

  10. Fuchs H, Pincus T: Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994, 37:470–475.

    Article  PubMed  CAS  Google Scholar 

  11. Husted J, Gladman D, Farewell V, Cook R: Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45:151–158. An important paper that explores functional status and QOL in PsA patients.

    Article  PubMed  CAS  Google Scholar 

  12. Fries J, Spitz P, Kraines R, et al.: Measurement of patient outcomes in arthritis. Arthritis Rheum 1980, 23:137–145.

    Article  PubMed  CAS  Google Scholar 

  13. Mease P, Ganguly L, Wanke E, et al.: How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004, 63(Suppl 1):391.

    Google Scholar 

  14. Husted J, Gladman D, Farewell V, et al.: Validation of the revised and expanded version of the arthritis impact measurement scales for patients with psoriatic arthritis. J Rheumatol 1996, 23:1015–1019.

    PubMed  CAS  Google Scholar 

  15. Clegg D, Reda D, Mejias E, et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a department of Veterans Affairs cooperative study. Arthritis Rheum 1996, 39:2013–2020.

    Article  PubMed  CAS  Google Scholar 

  16. Felson D, Anderson J, Boers M, et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727–735.

    Article  PubMed  CAS  Google Scholar 

  17. Felson D, Anderson J, Lange M, et al.: Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather then twenty percent? Arthritis Rheum 1998, 41:1564–1570.

    PubMed  CAS  Google Scholar 

  18. vanGestel A, Prevoo M, Hof M, et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis; comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996, 39:34–40.

    Article  PubMed  Google Scholar 

  19. vanGestel A, Anderson J, van Riel P, et al.: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999, 26:705–711.

    PubMed  Google Scholar 

  20. Mease PJ, Gladman DD, Krueger GG: Psoriatic Arthritis: Group for Research and Assessment in Psoriasis and Psoriatic Arthritis (GRAPPA). Ann Rheum Dis 2005, 64(Suppl 2):ii1-ii2.

    Article  Google Scholar 

  21. Gladman D, Strand V, Mease P, et al.: OMERACT psoriatic arthritis workshop: synopsis. Ann Rheum Dis 2005, 64(Suppl 2):ii115-ii116.

    Article  PubMed  Google Scholar 

  22. Taylor W, Porter G, Helliwell P: Operational definitions and observer reliability of the plain radiographic features of psoriatic arthritis. J Rheumatol 2003, 30:2645–2658. A careful assessment of radiographic methods for PsA.

    PubMed  Google Scholar 

  23. Rahman P, Gladman D, Cook R, et al.: Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998, 37:760–765.

    Article  PubMed  CAS  Google Scholar 

  24. Wassenberg S, Fischer O, Kahle V, et al.: A method to score radiographic changes in PsA. Z Rheumatol 2001, 60:156–166.

    Article  PubMed  CAS  Google Scholar 

  25. Mease P, Kivitz A, Burch F, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264–2272. A phase III study of etanercept in patients with PsA. This report provides key information on radiographic changes, along with detailed clinical responses to treatment with this tumor necrosis factor inhibitor.

    Article  PubMed  CAS  Google Scholar 

  26. Husted J, Gladman D, Farewell V, et al.: Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24:511–517.

    PubMed  CAS  Google Scholar 

  27. McKenna A, Doward L, Whalley D, et al.: Development of the PsAQOL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004, 63:162–169. A carefully performed assessment of QOL issues specific to patients with PsA.

    Article  PubMed  CAS  Google Scholar 

  28. Antoni C, Kavanaugh A, Kirkham B, et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227–1236. A phase II study of infliximab in patients with PsA. This report provides information on dactylitis and enthesitis, along with detailed clinical responses to treatment with this tumor necrosis factor inhibitor.

    Article  PubMed  CAS  Google Scholar 

  29. Antoni C, Krueger G, de Vlam K, et al.: {btInfliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial}. Ann Rheum Dis 2005, In press. A phase III study of infliximab in patients with PsA. This report provides information on dactylitis and enthesitis, along with detailed clinical responses to treatment with this tumor necrosis factor inhibitor.

  30. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al.: Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003, 62:127–132.

    Article  PubMed  CAS  Google Scholar 

  31. van derHeijde D, van der Linden S, Dougadas M, et al.: Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 1999, 26:1003–1005.

    PubMed  Google Scholar 

  32. Ashcroft D, Po A, Williams H, Griffiths C: Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of quality. Br J Dermatol 1999, 141:185–191.

    Article  PubMed  CAS  Google Scholar 

  33. de Korte J, Mombers F, Sprangers M, Bos J: The suitability of quality-of-life measures for psoriasis research. Arch Dermatol 2002, 138:1221–1227. A systematic review of various instruments developed to assess QOL in psoriasis.

    Article  PubMed  Google Scholar 

  34. Mazzotti E, Picardi A, Sampogna F, et al.: Sensitivity of the Dermatology life quality index to clinical change in patients with psoriasis. Br J Dermatol 2003, 149:318–322.

    Article  PubMed  CAS  Google Scholar 

  35. Rich P, Scher R: Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003, 49:206–212. Development of a method to assess nail related changes in psoriasis.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Allergy, and Immunology, University of California San Diego, 9500 Gilman Drive, 92093-0943, La Jolla, CA, USA

    Arthur Kavanaugh MD

Authors
  1. Arthur Kavanaugh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah Cassell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kavanaugh, A., Cassell, S. Outcome measures in psoriatic arthritis. Curr Rheumatol Rep 7, 195–200 (2005). https://doi.org/10.1007/s11926-996-0039-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-996-0039-x

Keywords

Search

Navigation